Answers are grounded in this paper and cite their sources.
Background Sepsis and septic shock, as critical complications caused by severe infections in current clinical practice, continue to exhibit persistently high morbidity and mortality rates. This study aims to utilize Picco monitoring data to investigate the differences in vasopressor effects and clinical outcomes between norepinephrine monotherapy and norepinephrine combined with dopamine therapy in sepsis and septic shock. Method A total of 83 patients with septic shock were retrospectively included. All of them received adequate fluid resuscitation and were primarily treated with norepinephrine (NE) alone or NE combined with dopamine (DA) to maintain a mean arterial pressure (MAP) of 65 mmHg. Hemodynamic parameters, including mean arterial pressure (MAP), cardiac output, and systemic vascular resistance, were closely monitored using Pulse - Indicated Continuous Cardiac Output (PICCO) technology throughout the study period. Results The study results revealed that, compared to the NE group, patients in the NE + DA group had higher APACHE II scores (mean in the NE group: 21.34 vs mean in the NE + DA group: 26.87, P < 0.001). No significant differences were found between the two groups in terms of the vasopressor effects on sepsis complications, including acute respiratory distress syndrome (ARDS) (81.1% in the NE group vs 76.7% in the NE + DA group) and acute kidney injury (AKI) (66% in the NE group vs 83.3% in the NE + DA group). However, there was no difference in mechanical ventilation for these two major complications between the groups (mechanical ventilation: 79.2% in the NE group vs 76.7% in the NE + DA group), but there was a difference in continuous renal replacement therapy (CRRT) (CRRT: 39.6% in the NE group vs 73.3% in the NE + DA group, P = 0.006). Logistic regression analysis identified higher Acute Physiology and Chronic Health Evaluation II scores (OR = 1.26, p = 0.0001) and the use of DA + NE vasopressors (OR = 4.52, p = 0.039) as significant risk factors for mortality in patients with septic shock. Furthermore, the 7 - day mortality rate was 33.3% (10/83) in the DA + NE group when used as vasopressors, compared to 5.7% (3/83) in the NE treatment group (P = 0.003). The 28 - day mortality rate was 53.3% (16/83) in the DA + NE group versus 13.2% (7/83) in the NE treatment group (P < 0.001).In exploring potential reasons, we utilized PICCO to monitor hemodynamic data, including heart rate (HR), lactate (Lac), and mean arterial pressure (MAP). The study found that NE + DA increased lactate levels in patients with septic shock at different time points, which may have directly contributed to patient mortality. Conclusion In summary, this study indicates that compared with the use of norepinephrine alone, the use of norepinephrine in conjunction with dopamine (DA) for the treatment of septic shock does not effectively improve the patient's condition. NE monotherapy may represent a preferable vasopressor strategy; however, the observed association requires confirmation in prospective studies. Consequently, it is necessary to reassess these treatment modalities and investigate more efficacious strategies for managing septic shock.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: